{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:46:41Z","timestamp":1789685201049,"version":"4.0.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sleep Breath"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s11325-026-03748-2","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T10:42:54Z","timestamp":1782556974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["GLP-1 receptor agonists and Risk of Cardiovascular and Pulmonary Complications in patients with OSA and Type 2 Diabetes Mellitus"],"prefix":"10.1007","volume":"30","author":[{"given":"Martin","family":"Borissov Borissov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9845-7073","authenticated-orcid":false,"given":"Soo Young","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emerson M.","family":"Wickwire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer Y.","family":"So","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"issue":"9918","key":"3748_CR1","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/s0140-6736(13)60734-5","volume":"383","author":"AS Jordan","year":"2014","unstructured":"Jordan AS, McSharry DG, Malhotra A (2014) Adult obstructive sleep apnoea. Lancet 383(9918):736\u2013747. https:\/\/doi.org\/10.1016\/s0140-6736(13)60734-5","journal-title":"Lancet"},{"key":"3748_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2025.108348","volume":"248","author":"I S\u00f6nmez","year":"2025","unstructured":"S\u00f6nmez I, Vo Dupuy A, Yu KS, Cronin J, Yee J, Azarbarzin A (2025) Unmasking obstructive sleep apnea: estimated prevalence and impact in the United States. Respir Med 248:108348. https:\/\/doi.org\/10.1016\/j.rmed.2025.108348","journal-title":"Respir Med"},{"issue":"3","key":"3748_CR3","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1161\/CIR.0000000000000988","volume":"144","author":"Y Yeghiazarians","year":"2021","unstructured":"Yeghiazarians Y, Jneid H, Tietjens JR, Redline S, Brown DL, El-Sherif N et al (2021) Obstructive sleep apnea and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 144(3):e56\u2013e67. https:\/\/doi.org\/10.1161\/CIR.0000000000000988","journal-title":"Circulation"},{"key":"3748_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19095473","author":"BW Locke","year":"2022","unstructured":"Locke BW, Lee JJ, Sundar KM (2022) OSA and chronic respiratory disease: mechanisms and epidemiology. Int J Environ Res Public Health. https:\/\/doi.org\/10.3390\/ijerph19095473","journal-title":"Int J Environ Res Public Health"},{"key":"3748_CR5","unstructured":"FDA Approves First Medication for Obstructive Sleep Apnea. (2024). Accessed Oct 16th, 2025 2025."},{"issue":"13","key":"3748_CR6","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","volume":"391","author":"A Malhotra","year":"2024","unstructured":"Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A et al (2024) Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med 391(13):1193\u20131205. https:\/\/doi.org\/10.1056\/NEJMoa2404881","journal-title":"N Engl J Med"},{"issue":"20","key":"3748_CR7","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/j.jacc.2025.08.027","volume":"86","author":"M Galli","year":"2025","unstructured":"Galli M, Benenati S, Laudani C, Simeone B, Sarto G, Ortega-Paz L et al (2025) Cardiovascular effects and tolerability of GLP-1 receptor agonists. JACC 86(20):1805\u20131819. https:\/\/doi.org\/10.1016\/j.jacc.2025.08.027","journal-title":"JACC"},{"issue":"10","key":"3748_CR8","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1164\/rccm.202303-0491OC","volume":"208","author":"D Foer","year":"2023","unstructured":"Foer D, Strasser ZH, Cui J, Cahill KN, Boyce JA, Murphy SN et al (2023) Association of GLP-1 receptor agonists with chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes. Am J Respir Crit Care Med 208(10):1088\u20131100. https:\/\/doi.org\/10.1164\/rccm.202303-0491OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"3748_CR9","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.jaci.2017.11.043","volume":"142","author":"S Toki","year":"2018","unstructured":"Toki S, Goleniewska K, Reiss S, Zhang J, Bloodworth MH, Stier MT et al (2018) Glucagon-like peptide 1 signaling inhibits allergen-induced lung IL-33 release and reduces group 2 innate lymphoid cell cytokine production in vivo. J Allergy Clin Immunol 142(5):1515\u201328. e8","journal-title":"J Allergy Clin Immunol"},{"key":"3748_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071380","volume":"379","author":"R Pradhan","year":"2022","unstructured":"Pradhan R, Lu S, Yin H, Yu OHY, Ernst P, Suissa S et al (2022) Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study. BMJ 379:e071380. https:\/\/doi.org\/10.1136\/bmj-2022-071380","journal-title":"BMJ"},{"key":"3748_CR11","unstructured":"TriNetX LLC (2024) TriNetX Research Network. TriNetX LLC. https:\/\/trinetx.com. Accessed May 2025"},{"issue":"6","key":"3748_CR12","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1080\/15412555.2021.1950663","volume":"18","author":"A Lurie","year":"2021","unstructured":"Lurie A, Roche N (2021) Obstructive sleep apnea in patients with chronic obstructive pulmonary disease: facts and perspectives. COPD 18(6):700\u2013712","journal-title":"COPD"},{"issue":"4","key":"3748_CR13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/cea.14284","volume":"53","author":"D Foer","year":"2023","unstructured":"Foer D, Beeler PE, Cui J, Snyder WE, Mashayekhi M, Nian H et al (2023) Glucagon-like peptide-1 receptor agonist use is associated with lower serum periostin. Clin Exp Allergy 53(4):469","journal-title":"Clin Exp Allergy"},{"issue":"4","key":"3748_CR14","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1001\/jamainternmed.2024.7811","volume":"185","author":"A Ray","year":"2025","unstructured":"Ray A, Paik JM, Wexler DJ, Sreedhara SK, Bykov K, Feldman WB et al (2025) Glucose-lowering medications and risk of chronic obstructive pulmonary disease exacerbations in patients with type 2 diabetes. JAMA Intern Med 185(4):399\u2013410. https:\/\/doi.org\/10.1001\/jamainternmed.2024.7811","journal-title":"JAMA Intern Med"},{"issue":"6","key":"3748_CR15","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1111\/resp.13107","volume":"22","author":"RL Owens","year":"2017","unstructured":"Owens RL, Macrea MM, Teodorescu M (2017) The overlaps of asthma or COPD with OSA: a focused review. Respirology 22(6):1073\u20131083. https:\/\/doi.org\/10.1111\/resp.13107","journal-title":"Respirology"},{"key":"3748_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2025.108197","volume":"245","author":"DH Cooper","year":"2025","unstructured":"Cooper DH, Akbarian N, Aaron SD, Luks V, Kendzerska T (2025) Glucagon-like peptide 1 (GLP-1) receptor agonists and asthma and COPD exacerbations in adults with diabetes: a systematic review. Respir Med 245:108197. https:\/\/doi.org\/10.1016\/j.rmed.2025.108197","journal-title":"Respir Med"},{"issue":"1","key":"3748_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1001\/jamainternmed.2024.5982","volume":"185","author":"B Lee","year":"2025","unstructured":"Lee B, Man KKC, Wong E, Tan T, Sheikh A, Bloom CI (2025) Antidiabetic medication and asthma attacks. JAMA Intern Med 185(1):16\u201325. https:\/\/doi.org\/10.1001\/jamainternmed.2024.5982","journal-title":"JAMA Intern Med"},{"key":"3748_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04071-1","author":"A Malhotra","year":"2026","unstructured":"Malhotra A, Grunstein R, Azarbarzin A, Sands S, Somers VK, Aronne LJ et al (2026) Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial. Nat Med. https:\/\/doi.org\/10.1038\/s41591-025-04071-1","journal-title":"Nat Med"},{"issue":"5","key":"3748_CR19","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/s2213-2600(25)00002-5","volume":"13","author":"AV Benjafield","year":"2025","unstructured":"Benjafield AV, Pepin JL, Cistulli PA, Wimms A, Lavergne F, Sert Kuniyoshi FH et al (2025) Positive airway pressure therapy and all-cause and cardiovascular mortality in people with obstructive sleep apnoea: a systematic review and meta-analysis of randomised controlled trials and confounder-adjusted, non-randomised controlled studies. Lancet Respir Med 13(5):403\u2013413. https:\/\/doi.org\/10.1016\/s2213-2600(25)00002-5","journal-title":"Lancet Respir Med"},{"issue":"8","key":"3748_CR20","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/ijo.2016.52","volume":"40","author":"A Blackman","year":"2016","unstructured":"Blackman A, Foster GD, Zammit G, Rosenberg R, Aronne L, Wadden T et al (2016) Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE sleep apnea randomized clinical trial. Int J Obes (Lond) 40(8):1310\u20131319. https:\/\/doi.org\/10.1038\/ijo.2016.52","journal-title":"Int J Obes (Lond)"},{"key":"3748_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/diseases12090224","author":"S Dragonieri","year":"2024","unstructured":"Dragonieri S, Portacci A, Quaranta VN, Carratu P, Lazar Z, Carpagnano GE et al (2024) Therapeutic potential of glucagon-like peptide-1 receptor agonists in obstructive sleep apnea syndrome management: a narrative review. Diseases. https:\/\/doi.org\/10.3390\/diseases12090224","journal-title":"Diseases"}],"container-title":["Sleep and Breathing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11325-026-03748-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11325-026-03748-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11325-026-03748-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T12:59:24Z","timestamp":1787144364000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11325-026-03748-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3748"],"URL":"https:\/\/doi.org\/10.1007\/s11325-026-03748-2","relation":{},"ISSN":["1520-9512","1522-1709"],"issn-type":[{"value":"1520-9512","type":"print"},{"value":"1522-1709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"7 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study is a secondary analysis of existing data which does not involve intervention or interaction with human subjects and is de-identified per the HIPAA Privacy Rule.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"EM Wickwire\u2019s institution has received research funding from the AASM Foundation, Department of Defense, Merck, NIH\/NIA, ResMed, the ResMed Foundation, and the SRS Foundation. EM Wickwire has served as a scientific consultant to Axsome Therapeutics, DayZz, Eisai, EnsoData, Idorsia, Merck, Nox Health, Primasun, Purdue, and ResMed and is an equity shareholder in WellTap.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"199"}}